CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced its participation in the SVB Securities Global Biopharma Conference on February 15, 2023, at 3:40 PM Eastern Time. The event will be conducted in a virtual format and will feature a fireside chat. CymaBay specializes in developing therapies for liver diseases with high unmet needs, focusing on their lead candidate, seladelpar, for treating primary biliary cholangitis (PBC). The company has received several designations from health authorities, indicating its commitment to addressing significant medical challenges.

For more details, visit www.cymabay.com.

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

SVB Securities Global Biopharma Conference
Date:		Wednesday, February 15
Time:		3:40 pm Eastern Time
Location:		Virtual
Format:		Fireside Chat
Webcast:		http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Cautionary Statements
Any statements made in this press release and at the conference referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, and the timing of the release of seladelpar clinical data are forward-looking statements that are subject to risks and uncertainties. Actual outcomes and results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of product development activities; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of product candidates; and the ability to obtain sufficient financing to complete development, regulatory approval and commercialization of product candidates. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:                                    

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com 

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

When will CymaBay Therapeutics present at the SVB Securities Global Biopharma Conference?

CymaBay Therapeutics will present on February 15, 2023, at 3:40 PM Eastern Time.

What is the focus of CymaBay Therapeutics?

CymaBay Therapeutics focuses on developing therapies for liver diseases and other chronic conditions with high unmet medical needs.

What is seladelpar and its significance for CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis (PBC), which has received breakthrough therapy designation from the FDA.

What format will the CymaBay presentation take at the conference?

The presentation will be in the format of a fireside chat.

Where can I find more information about CymaBay Therapeutics?

More information can be found on their website at www.cymabay.com.